Previous Close | 22.65 |
Open | 22.11 |
Bid | 17.00 x 900 |
Ask | 21.22 x 800 |
Day's Range | 21.04 - 22.60 |
52 Week Range | 18.98 - 36.95 |
Volume | |
Avg. Volume | 569,281 |
Market Cap | 1.693B |
Beta (5Y Monthly) | 1.53 |
PE Ratio (TTM) | 27.25 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?